million new cases of cancer were diagnosed across 188 countries in 2013, and there were 8.2 million deaths [2] . Given this enormous number of people affected by different types of malignant disease, cancer prevention is a high priority-seeking to reduce the burden of cancers caused by environmental and behavioral factors such as tobacco smoke. Yet the aging of populations across high-income, middle-income, and low-income countries alike is expected to lead to ongoing increases in cancer incidence, substantially expanding the need for and costs of treatment and supportive care in all countries.
The field of cancer genomics is at an exciting juncture: especially promising results are emerging from immunotherapy and vaccine development programs. The forthcoming special issue of PLOS Medicine will focus on this area, and we invite submissions of research papers documenting the acquisition and use of genomic information to improve diagnosis, prognosis, or treatment of cancer. We will consider high-quality translational and clinical studies, and priority will be given to research articles describing novel methodologies or treatments that promise to lead to clinical benefit in common cancers or types of malignant disease in which there is a particular need for new treatment strategies.
We especially welcome submissions in the following areas:
• Characterization of genetic alterations leading to carcinogenesis or disease progression in patients, with clear demonstrated relevance for diagnosis or treatment.
• Cancer immunotherapy-novel approaches to harnessing the immune system to combat common cancers.
• Translational or clinical studies aimed at development of cancer vaccines, especially those informed by tumor genome alterations.
• New approaches based on liquid biopsy for disease detection and monitoring of treatment responses.
• Large-scale data analyses and decision-support tools that promise to be of particular importance in aiding cancer diagnosis, provision of prognostic information, and therapies.
Researchers who would like their work to be considered for this special issue should submit by Friday, 8 July 2016. Authors of submissions not selected for the issue may be offered transfer of their paper to PLOS ONE, before or after peer review, with the prospect of inclusion in a Collection on the Clinical Implications of Cancer Genomics, which will include papers published in both journals. Please submit your manuscript at this site: http://journals.plos.org/ plosmedicine/s/submit-now.
Authors are not required to send a pre-submission inquiry when submitting a manuscript for this special issue. Please indicate in your cover letter that you would like the full manuscript to be considered for the special issue and, if you would like to inquire about the suitability of a manuscript for consideration, please email the editors via plosmedicine@plos.org.
